DIA Biosimilars 2013

Targacept

Targacept initiates phase IIb study of TC-5214

Thursday, May 30, 2013 01:14 PM

Targacept, a clinical-stage biopharmaceutical company developing novel neuronal nicotinic receptors (NNR) therapeutics, plans the initiation of a phase IIb clinical study of TC-5214 as a treatment for overactive bladder (OAB). TC-5214 acts potently on alpha3beta4 and other NNRs located in or around the bladder  believed to play a key role in bladder contraction and signaling of the urge to urinate.

More... »

Cenduit: Now with Patient Reminders

Targacept to reduce workforce, refocus company

Wednesday, April 25, 2012 02:47 PM

Targacept, a N.C.-based clinical-stage biopharmaceutical company developing novel NNR Therapeutics, plans to reduce its workforce by 65 employees, approximately 46%, as part of a strategic plan to focus the company's resources on its clinical programs and select preclinical opportunities.

More... »

CRF Health – eCOA Forum

Targacept shows potential for schizophrenia

Tuesday, March 29, 2011 01:05 PM

Targacept’s results from a phase II trial of TC-5619 in non-smoker adults with ADHD show the compound did not meet the primary efficacy outcome measure.

More... »

GSK, Targacept end agreement

Friday, March 4, 2011 02:28 PM

GlaxoSmithKline has terminated a pact with Targacept that was exploring treatments for a variety of conditions, including smoking cessation, obesity and Parkinson’s disease, according to PharmaTimes.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.